InflaRx NV (InflaRx NV) Beginning Cash Position : $13.88 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is InflaRx NV Beginning Cash Position?

InflaRx NV's Beginning Cash Position for the quarter that ended in Mar. 2024 was $13.88 Mil.

InflaRx NV's quarterly Beginning Cash Position increased from Sep. 2023 ($20.83 Mil) to Dec. 2023 ($23.66 Mil) but then declined from Dec. 2023 ($23.66 Mil) to Mar. 2024 ($13.88 Mil).

InflaRx NV's annual Beginning Cash Position declined from Dec. 2021 ($29.34 Mil) to Dec. 2022 ($27.81 Mil) and declined from Dec. 2022 ($27.81 Mil) to Dec. 2023 ($17.74 Mil).

InflaRx NV Beginning Cash Position Historical Data

The historical data trend for InflaRx NV's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InflaRx NV Beginning Cash Position Chart

InflaRx NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

61.54

40.31

29.34

27.81

17.74

InflaRx NV Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial															17.41	2.27	20.83	23.66	13.88

InflaRx NV Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

InflaRx NV Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of InflaRx NV's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

InflaRx NV (InflaRx NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (NAS:IFRX) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

IF0:Germany IF0:Germany

Address

Winzerlaer Strasse 2, Jena, DEU, 07745

Website

https://www.inflarx.de

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.